MX2022003193A - Tratamiento de encefalopatia asociada al gen syngap1. - Google Patents

Tratamiento de encefalopatia asociada al gen syngap1.

Info

Publication number
MX2022003193A
MX2022003193A MX2022003193A MX2022003193A MX2022003193A MX 2022003193 A MX2022003193 A MX 2022003193A MX 2022003193 A MX2022003193 A MX 2022003193A MX 2022003193 A MX2022003193 A MX 2022003193A MX 2022003193 A MX2022003193 A MX 2022003193A
Authority
MX
Mexico
Prior art keywords
syngap1
encephalopathy
treatment
subject
cannabidiol
Prior art date
Application number
MX2022003193A
Other languages
English (en)
Inventor
John Messenheimer
Donna Gutterman
Terri Sebree
Original Assignee
Zynerba Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals Inc filed Critical Zynerba Pharmaceuticals Inc
Publication of MX2022003193A publication Critical patent/MX2022003193A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A61M21/02—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
    • A61M2021/0077—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus with application of chemical or pharmacological stimulus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente tecnología se relaciona a métodos para tratar la encefalopatía asociada al gen SINGAP1 por administrar transdérmicamente una cantidad efectiva de cannabidiol (CBD) al sujeto, en donde se trata un síntoma asociado al gen SINGAP1 en el sujeto.
MX2022003193A 2019-09-17 2020-09-16 Tratamiento de encefalopatia asociada al gen syngap1. MX2022003193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962901651P 2019-09-17 2019-09-17
PCT/US2020/051095 WO2021055493A1 (en) 2019-09-17 2020-09-16 Treatment of syngap1 encephalopathy

Publications (1)

Publication Number Publication Date
MX2022003193A true MX2022003193A (es) 2022-04-11

Family

ID=74869217

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022003193A MX2022003193A (es) 2019-09-17 2020-09-16 Tratamiento de encefalopatia asociada al gen syngap1.
MX2022003194A MX2022003194A (es) 2019-09-17 2020-09-16 Tratamiento de deterioro del comportamiento en la encefalopatia del desarrollo y epileptica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003194A MX2022003194A (es) 2019-09-17 2020-09-16 Tratamiento de deterioro del comportamiento en la encefalopatia del desarrollo y epileptica.

Country Status (12)

Country Link
US (2) US20210077421A1 (es)
EP (2) EP4031119A4 (es)
JP (2) JP2022547922A (es)
KR (2) KR20220066091A (es)
CN (2) CN114423416A (es)
AU (2) AU2020348310A1 (es)
BR (2) BR112022004175A2 (es)
CA (2) CA3151171A1 (es)
IL (2) IL291363A (es)
JO (2) JOP20220054A1 (es)
MX (2) MX2022003193A (es)
WO (2) WO2021055499A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2597322A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
EP4255402A1 (en) * 2020-12-03 2023-10-11 Zynerba Pharmaceuticals, Inc. Cannabidiol for the treatment of refractory seizures
WO2022162621A1 (en) * 2021-01-28 2022-08-04 Zynerba Pharmaceuticals, Inc. Treatment of sleep apnea with cbd
WO2022215030A1 (en) * 2021-04-08 2022-10-13 Pike Therapeutics Inc., 1219014 B.C. Ltd Pharmaceutical composition and method for treating seizure disorders
WO2023163801A1 (en) * 2022-02-24 2023-08-31 Q-State Biosciences, Inc. Therapeutics for syngap haploinsufficiency

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2531278A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
EP3253875B1 (en) * 2015-02-04 2020-01-08 H. Hoffnabb-La Roche Ag Tau antisense oligomers and uses thereof
BR112017018944A2 (pt) * 2015-03-02 2018-05-15 Afgin Pharma Llc método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s)
IL246790A0 (en) * 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
MX2020003004A (es) * 2017-09-19 2020-11-06 Zynerba Pharmaceuticals Inc Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos.
EP3703672A4 (en) * 2017-10-30 2021-12-01 Endocanna Health, Inc. CANNABINOID FORMULATIONS
GB2597322A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities

Also Published As

Publication number Publication date
CN114423416A (zh) 2022-04-29
US20220218625A1 (en) 2022-07-14
WO2021055499A1 (en) 2021-03-25
CA3151171A1 (en) 2021-03-25
IL291362A (en) 2022-05-01
EP4031120A1 (en) 2022-07-27
JOP20220061A1 (ar) 2023-01-30
IL291363A (en) 2022-05-01
CN114401713A (zh) 2022-04-26
EP4031119A4 (en) 2023-08-02
WO2021055493A1 (en) 2021-03-25
BR112022004175A2 (pt) 2022-05-31
MX2022003194A (es) 2022-04-11
CA3150617A1 (en) 2021-03-25
EP4031119A1 (en) 2022-07-27
JP2022547136A (ja) 2022-11-10
JOP20220054A1 (ar) 2023-01-30
BR112022004272A2 (pt) 2022-06-07
AU2020348310A1 (en) 2022-03-31
US20210077421A1 (en) 2021-03-18
AU2020350605A1 (en) 2022-03-31
KR20220063208A (ko) 2022-05-17
JP2022547922A (ja) 2022-11-16
KR20220066091A (ko) 2022-05-23
EP4031120A4 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
JOP20220054A1 (ar) علاج اعتلال الدماغ syngap1
MX2022012424A (es) Tratamiento del sindrome del cromosoma x fragil con canabidiol.
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
MX2020005547A (es) Moduladores de la actividad del complemento.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
JOP20200045A1 (ar) كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين
AU2016255707A8 (en) Uses of cannabidiol for treatment of infantile spasms
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
TN2019000019A1 (en) Treatment and prevention of sleep disorders
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
MX2019013862A (es) Terapia de combinacion.
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
MX2022014912A (es) Tratamiento del trastorno del espectro autista con cannabidiol.
BR112019008241A2 (pt) tratamento do prurigo nodular
MX2021003006A (es) Bacterioterapia contra proprionibacterium acnes para el tratamiento de acne.
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2021006778A (es) Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion.
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
JOP20210140A1 (ar) معالجة متلازمة الحذف 22q11.2 بكانابيديول
MX2023006551A (es) Tratamiento de las convulsiones refractarias.